Cargando…
SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital
PURPOSE: Multisystem inflammatory syndrome in children (MIS-C) – the most severe status, associated with SARS-COV-2 infection. Clinical and laboratory characteristics of MIS-C, and treatment optimization are topical problems on current stage. Our aim to analyze main features of the MIS-C. METHODS &a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884809/ http://dx.doi.org/10.1016/j.ijid.2021.12.099 |
_version_ | 1784660248215158784 |
---|---|
author | Novikov, D. Melekhina, E. Sabinina, T. Shalbarova, T. Cremplevskaya, S. Barykin, V. Muzyka, A. Ponezheva, Z. Pshenichnaya, N. |
author_facet | Novikov, D. Melekhina, E. Sabinina, T. Shalbarova, T. Cremplevskaya, S. Barykin, V. Muzyka, A. Ponezheva, Z. Pshenichnaya, N. |
author_sort | Novikov, D. |
collection | PubMed |
description | PURPOSE: Multisystem inflammatory syndrome in children (MIS-C) – the most severe status, associated with SARS-COV-2 infection. Clinical and laboratory characteristics of MIS-C, and treatment optimization are topical problems on current stage. Our aim to analyze main features of the MIS-C. METHODS & MATERIALS: We evaluated 41 children (21M/18F) 1 - 16 yrs. (8,45±0,677 yrs.) hospitalized in Khimki Regional Hospital with MIS-C from June 2020 to April 2021. 7 children had background disease (allergy, nephroblastoma, ulcerative colitis, diabetes mellitus, urologic pathology). 5 children were mongoloid race (12%). Excessive weight had 27%, according to BMI; 17% had high growth to age. 58% had A(II) blood group, Rh(+)-positive were 74%. RESULTS: All children at the admission had fever more than 3 days. Anti-SARS-COV-2 IgM and IgG had 1 patient, IgG only - 25 (61%); 2 patients were positive SARS-Cov2 RNA in the oropharyngeal swab; 27% had family contact to СOVID-19. By severity 66% children were hospitalized to the ICU. Clinically skin and mucosal signs had 31 (76 %), gastro-intestinal symptoms – 22 (54%), pneumonia – 20 (49%), kidney injury –15 (40%), cardiovascular damage - 10 (24%), CNS –6 (15%). Simultaneous damage of 2 systems had 37% children, 3 – 46%, 4 - 12%, 5 – 1 patient, 6 – 1 patient. 5 cases developed acute kidney injury like hemolytic-uremic syndrome (HUS), as the main MIS-C performance. Laboratory features: increased ESR (Мe 40,0 (IQR 30-50) мм/ч), elevated CRP (Мe 118,9 (IQR 71,5-129,4)), ferritin (Мe 471,0 (IQR 214,08-990,28)), D-dimer (Мe 2,81 (IQR 1,76 – 4,55)), LDH (Мe 594,0 (IQR 511,0-663,0)), CK (Мe 112,0 (IQR 61,35-288,7)), CK-MB (Мe 44,95 (IQR 33,0-80,1)), decreased albumin (Мe 27,4 (IQR 23,0-33,0)). In 76% patients were treated with methylprednisolone pulse, IVIG in 20%, standard doses of corticosteroids – 10%. All children discharged home with recovery. CONCLUSION: MIS-C is the most severe form of COVID-19 in children. In Khimki Regional Hospital 41 patient were successfully treated. The main features are severe status (66%-ICU), 63% children had 3+ affected systems; the main symptoms are skin and mucosal damage, gastrointestinal signs and headache, high BMI. There were 5 patients with HUS, during SARS-Cov2 associated MIS-C. |
format | Online Article Text |
id | pubmed-8884809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88848092022-03-01 SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital Novikov, D. Melekhina, E. Sabinina, T. Shalbarova, T. Cremplevskaya, S. Barykin, V. Muzyka, A. Ponezheva, Z. Pshenichnaya, N. Int J Infect Dis Ps05.07 (121) PURPOSE: Multisystem inflammatory syndrome in children (MIS-C) – the most severe status, associated with SARS-COV-2 infection. Clinical and laboratory characteristics of MIS-C, and treatment optimization are topical problems on current stage. Our aim to analyze main features of the MIS-C. METHODS & MATERIALS: We evaluated 41 children (21M/18F) 1 - 16 yrs. (8,45±0,677 yrs.) hospitalized in Khimki Regional Hospital with MIS-C from June 2020 to April 2021. 7 children had background disease (allergy, nephroblastoma, ulcerative colitis, diabetes mellitus, urologic pathology). 5 children were mongoloid race (12%). Excessive weight had 27%, according to BMI; 17% had high growth to age. 58% had A(II) blood group, Rh(+)-positive were 74%. RESULTS: All children at the admission had fever more than 3 days. Anti-SARS-COV-2 IgM and IgG had 1 patient, IgG only - 25 (61%); 2 patients were positive SARS-Cov2 RNA in the oropharyngeal swab; 27% had family contact to СOVID-19. By severity 66% children were hospitalized to the ICU. Clinically skin and mucosal signs had 31 (76 %), gastro-intestinal symptoms – 22 (54%), pneumonia – 20 (49%), kidney injury –15 (40%), cardiovascular damage - 10 (24%), CNS –6 (15%). Simultaneous damage of 2 systems had 37% children, 3 – 46%, 4 - 12%, 5 – 1 patient, 6 – 1 patient. 5 cases developed acute kidney injury like hemolytic-uremic syndrome (HUS), as the main MIS-C performance. Laboratory features: increased ESR (Мe 40,0 (IQR 30-50) мм/ч), elevated CRP (Мe 118,9 (IQR 71,5-129,4)), ferritin (Мe 471,0 (IQR 214,08-990,28)), D-dimer (Мe 2,81 (IQR 1,76 – 4,55)), LDH (Мe 594,0 (IQR 511,0-663,0)), CK (Мe 112,0 (IQR 61,35-288,7)), CK-MB (Мe 44,95 (IQR 33,0-80,1)), decreased albumin (Мe 27,4 (IQR 23,0-33,0)). In 76% patients were treated with methylprednisolone pulse, IVIG in 20%, standard doses of corticosteroids – 10%. All children discharged home with recovery. CONCLUSION: MIS-C is the most severe form of COVID-19 in children. In Khimki Regional Hospital 41 patient were successfully treated. The main features are severe status (66%-ICU), 63% children had 3+ affected systems; the main symptoms are skin and mucosal damage, gastrointestinal signs and headache, high BMI. There were 5 patients with HUS, during SARS-Cov2 associated MIS-C. Published by Elsevier Ltd. 2022-03 2022-02-28 /pmc/articles/PMC8884809/ http://dx.doi.org/10.1016/j.ijid.2021.12.099 Text en Copyright © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Ps05.07 (121) Novikov, D. Melekhina, E. Sabinina, T. Shalbarova, T. Cremplevskaya, S. Barykin, V. Muzyka, A. Ponezheva, Z. Pshenichnaya, N. SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
title | SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
title_full | SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
title_fullStr | SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
title_full_unstemmed | SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
title_short | SARS-CoV2-associated multisystem inflammatory syndrome in children: data from Khimki hospital |
title_sort | sars-cov2-associated multisystem inflammatory syndrome in children: data from khimki hospital |
topic | Ps05.07 (121) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884809/ http://dx.doi.org/10.1016/j.ijid.2021.12.099 |
work_keys_str_mv | AT novikovd sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT melekhinae sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT sabininat sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT shalbarovat sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT cremplevskayas sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT barykinv sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT muzykaa sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT ponezhevaz sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital AT pshenichnayan sarscov2associatedmultisysteminflammatorysyndromeinchildrendatafromkhimkihospital |